- Nurix Therapeutics press release (NASDAQ:NRIX): Q4 GAAP EPS of -$0.77 misses by $0.38.
- Revenue of $15.2M (+124.2% Y/Y) misses by $21.34M.
- Cash, cash equivalents and marketable securities was $295.3 million as of November 30, 2023, compared to $268.7 million as of August 31, 2023.
